Teva Pharmaceutical Industries (TEVA) Net Cash Flow Growth (1y) (2010 - 2026)
Teva Pharmaceutical Industries (TEVA) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 31.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.27% |
| Mar 31, 2026 | 112.26% |
| Dec 31, 2025 | 1,223.30% |
| Sep 30, 2025 | -94.69% |
| Jun 30, 2025 | 168.47% |
| Mar 31, 2025 | -1,158.02% |
| Dec 31, 2024 | -88.67% |
| Sep 30, 2024 | 348.32% |
| Jun 30, 2024 | -219.96% |
| Mar 31, 2024 | 80.45% |
| Dec 31, 2023 | 111.40% |
| Sep 30, 2023 | -254.18% |
| Jun 30, 2023 | 1,686.11% |
| Mar 31, 2023 | -687.72% |
| Dec 31, 2022 | 113.93% |
| Sep 30, 2022 | 169.72% |
| Jun 30, 2022 | -105.16% |
| Mar 31, 2022 | 129.23% |
| Dec 31, 2021 | -42.07% |
| Sep 30, 2021 | 39.29% |